Results 161 to 170 of about 81,297 (236)

Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Eur J Med Res
Baseri S, Izadi M, Alimohammadi M, Khoshnazar SM, Nikdel R, Hushmandi K.   +5 more
europepmc   +1 more source

Assessment of Quality of Care Provided for Patients Receiving Post‐Myocardial Infarction Care at Selected Cardiac Clinics in Sulaymaniyah: Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias, Yara Sarwar Hamid, Mende Mensa Sorato   +2 more
wiley   +1 more source

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. [PDF]

Int J Mol Sci
Tantawy M, Wang D, Gbadamosi M, Yu F, Zhang Y, Alomar ME, Shain KH, Baz RC, Bruno KA, Gong Y.   +9 more
europepmc   +1 more source

Dermatomyositis Like Presentation of Anti‐HMGCR Immune Mediated Necrotising Myopathy

JEADV Clinical Practice, Volume 5, Issue 1, Page 237-240, March 2026.
Capsule summary Cutaneous manifestations of HMGCR‐IMNM are rare and poorly described. Dermatomyositis‐like rash manifestation can be a presentation of the HMGCR‐IMNM. We report a case with a dermatomyositis‐like presentation and provide a literature review on this topic.
Lionel Leblanc, Lyna Mtimet, Louis Wolff, Evelyne Berlingin, Bruno Couturier   +4 more
wiley   +1 more source

Effects of rosuvastatin treatment and other statins on burn wound healing. [PDF]

World J Methodol
Marneri AG, Pavlidis ET, Stavrati KE, Mouratidou C, Kotoulas SC, Ballas KD, Pavlidis TE.   +6 more
europepmc   +1 more source

Rosuvastatin Upregulates RCOR1 to Repress C10ORF10 Transcription and Alleviate Oxidative Stress and Plaque Formation in Atherosclerosis

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 3, March 2026.
ABSTRACT Rosuvastatin (RVS) is an HMG‐CoA reductase inhibitor with lipid‐lowering properties. This study aims to investigate the role of RVS in plaque formation in atherosclerosis (AS) and its functional mechanism. ApoE−/− mice were fed a high‐fat diet to generate a mouse model of AS.
Xin Fu, Chuang Liu, Ya‐Li Chen, Jie‐Lin Qin, Ting‐Ting Wang, Shan‐Shan Fu   +5 more
wiley   +1 more source

Biochemical urine analysis of atorvastatin and rosuvastatin by LC-MS: a pilot study of an objective method to assess non-adherence. [PDF]

BMC Cardiovasc Disord
Brockmeyer M, Chernyak N, Dröge D, Wessel H, Parco C, Hoss A, Vargas KG, Lin Y, Rickert A, Ritz S, Icks A, Kelm M, Wolff G, Temme O.   +13 more
europepmc   +1 more source

Severe Renal Phenotype Across A Multigenerational Tuberous Sclerosis Complex (TSC) Family

Molecular Genetics &Genomic Medicine, Volume 14, Issue 3, March 2026.
A five generation family with a known pathogenic variant (c.1372C>T; p.Arg458*) in TSC2 displaying a severe renal phenotype characterized by large angiomyolipomas, renal cystic disease, and chronic kidney disease leading to renal failure. Our report illustrates a possible genotype–phenotype and highlights the importance of establishing genotype ...
Elena Tuller, Joshua A. Samuels, Hope Northrup, Kate Richardson   +3 more
wiley   +1 more source

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. [PDF]

Adv Ther
Qian J, Zhang X, Chen J, Ding C, Yang P, Qing L, Liu Y, Chen SS, Ge J.   +8 more
europepmc   +1 more source

Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders

Neuroprotection, Volume 4, Issue 1, Page 30-47, March 2026.
The graphical abstract encapsulates the dual neuroprotective mechanisms of statins in neurodegenerative diseases, highlighting both cholesterol‐dependent and cholesterol‐independent pathways. By inhibiting 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, statins reduce cholesterol synthesis, leading to altered lipid raft structures that ...
Jun Han Kuan, Roshan S. Raghavan, Dawn Li Wei Koh, Wing Yeng Tan, Igor Iezhitsa, Renu Agarwal   +5 more
wiley   +1 more source